Evidence map›Paper›PMID 31264168›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2019

Evaluation of neurotensin receptor 1 as potential biomarker for prostate cancer theranostic use.

Tingting He, Mengzhe Wang, Hui Wang, Hongpei Tan, Yongxiang Tang, Eric Smith, Zhanhong Wu, Weihua Liao, Shuo Hu, Zibo Li

Abstract readEvaluation Study
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 25 citations in OpenAlex.

  1. First-in-human evaluation of [Annals of medicine · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Neurotensin and Its Involvement in Female Hormone-Sensitive Cancers.International journal of molecular sciences · 2024
    Review
  6. Article
  7. Article
  8. Article
  9. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022
    Article
  10. Article
  11. Review
  12. Expression of neurotensin receptor-1 (NTSBreast cancer research and treatment · 2021
    Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Tingting He *PET Center of Xiangya Hospital, Central South University, Changsha, China.
Mengzhe Wang *Department of Radiology and Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Hui WangDepartment of Radiology and Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Hongpei TanPET Center of Xiangya Hospital, Central South University, Changsha, China.
Yongxiang TangPET Center of Xiangya Hospital, Central South University, Changsha, China.
Eric SmithDepartment of Radiology and Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Zhanhong WuDepartment of Radiology and Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Weihua LiaoDepartment of Radiology of Xiangya Hospital, Central South University, Changsha, China. ouwenliao@163.com.
Shuo HuPET Center of Xiangya Hospital, Central South University, Changsha, China. hushuoxy@csu.edu.cn.
Zibo LiDepartment of Radiology and Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. zibo_li@med.unc.edu.ORCID http://orcid.org/0000-0002-1063-0298
Central South University · CNUniversity of North Carolina at Chapel Hill · US

Funding

National Natural Science Foundation of China 81471689, 91859207, and 81771873
6 · The paper itself

Abstract

introductionDespite recent developments in the diagnosis and treatment of prostate cancer, the advanced stages still have poor survival rates. This warrants further exploration of related molecular targets for patient screening, detection of metastatic disease, and treatment/treatment monitoring. Recent studies have indicated that neurotensin receptors (NTSRs) and their ligand neurotensin (NTS) critically affect the progression of prostate cancers. In this study, we evaluated the expression of neurotensin receptor1 (NTSR1) in patient tissues and performed NTSR1 PET imaging in a prostate cancer animal model.

methodsThe NTSR1 expression was evaluated in 97 cases of prostate cancer and 100 cases of benign prostatic hyperplasia (BPH) of clinical patients by immunohistochemistry staining. The expression profile of PSMA and GRPR was also performed for comparison. The mRNA expression of NTSR1 in LnCap and PC-3 cells was measured by PCR. NTSR1 PET, and biodistribution studies were performed in PC-3 xenografts using

resultsNTSR1 showed high or moderate expression in 91.8% of prostate cancer tissue, compared with PSMA (86.7%) and GRPR (65.3%). All examined PSMA-negative tissues showed positive NTSR1 expression, suggesting the potential complementary role of NTSR1 targeted imaging or therapy. Only 8% of BPH shows strong or moderate expression of NTSR1, which is significantly lower than that in prostate cancer (91.8%). PCR results indicated LNCap (an androgen-dependent prostate cancer cell) showed negative NTSR1 expression while PC-3 demonstrated positive expression (an androgen-independent prostate cancer cell), which correlated well with previously reported western blot results. In a preclinical animal model, NTSR1 targeted PET probe

conclusionWe have demonstrated that NTSR1 is a promising molecular marker for prostate cancer based on patient tissue staining. The NTSR targeted probe

Indexed as

AgedAnimalsBiomarkers, TumorCarcinomaCell Line, TumorHumansMaleMiceMiddle AgedNeurotensinPositron-Emission TomographyProstatic NeoplasmsRadiopharmaceuticalsReceptors, NeurotensinRNA, MessengerTheranostic NanomedicineBiomarkers, TumorNeurotensinneurotensin type 1 receptorRadiopharmaceuticalsReceptors, NeurotensinRNA, Messenger18FNeurotensin receptorPositron emission tomography (PET)Prostate cancerProstate specific membrane antigen (PSMA)

Identifiers

PMID31264168
OpenAlexW2955556249

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.